There are currently 1572 clinical trials in Dallas, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Texas Southwestern Medical Center, UT Southwestern Medical Center, UT Southwestern/Simmons Cancer Center-Dallas and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Childhood Cancer Survivor Study
NCT01120353
Recruiting
The Childhood Cancer Survivor Study (CCSS) will investigate the long-term effects of cancer and its associated therapies. A retrospective cohort study will be conducted through a multi-institutional collaboration, which will involve the identification and active follow-up of a cohort of approximately 50,000 survivors of cancer, diagnosed before 21 years of age, between 1970 and 1999 and 10,000 sibling controls. This project will study children and young adults exposed to specific therapeutic mod... Read More
Gender:
All
Ages:
All
Trial Updated:
12/11/2023
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Cancer
Register for Updates
Establishing Normative Data for Pupillometer Assessments in Neuro-Intensive Care
NCT02804438
Recruiting
The purpose of this study is to collect a large amount of data that may assist in addressing the gap in knowledge of understanding pupillometer readings using a pupillometer device. The aim of this project is to establish normative values for pupillometer data. Measures of central tendency will be developed for the variables provided by automated pupillary exams, which will provide an enhanced understanding of clinically appropriate pupil values for size, reactivity, and neurological pupil inde... Read More
Gender:
All
Ages:
All
Trial Updated:
12/06/2023
Locations: Maria E Denbow, Dallas, Texas
Conditions: Critical Illness, Neuropathy
Register for Updates
Pathophysiology of Uric Acid Nephrolithiasis
NCT00904046
Recruiting
This study has two aims: Aim 1: To determine the presence of accumulation of fat within cells and the functional consequences of this in the kidney by correlating kidney fat content with urine test results. Aim 2: The investigators will evaluate the effect of thiazolidinedione (pioglitazone) on excess fatty acid accumulation in kidney tissue and its correlation with uric acid stone formation in subjects with uric acid stones. Pioglitazone is already U.S. Food & Drug Administration (FDA)-appro... Read More
Gender:
All
Ages:
Between 21 years and 99 years
Trial Updated:
12/06/2023
Locations: UT Southwestern Medical Center - Center for Mineral Metabolism, Dallas, Texas
Conditions: Uric Acid Kidney Stone Disease
Register for Updates
Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance
NCT03769766
Recruiting
This is a prospective study to determine if the use of curcumin randomized against placebo will reduce cancer progression in patients with prostate cancer undergoing active surveillance.
Gender:
Male
Ages:
Between 40 years and 89 years
Trial Updated:
12/06/2023
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Prostate Cancer
Register for Updates
A 2-part Study Consisting of Multiple Ascending Dose (MAD) Safety Study, and a Dose-finding Masked Study to Assess the Safety and Efficacy of Intravitreal (IVT) EYE103 in Patients With Diabetic Macular Edema (DME) or Neovascular Age-related Macular Degeneration (NVAMD)
NCT05919693
Recruiting
EYE103-101 is a 2-part study assessing safety and preliminary efficacy of EYE103 in patients with diabetic macular edema (DME) given as monotherapy or neovascular macular degeneration (NVAMD) given in combination with anti-VEGF. In the first part, termed the multiple ascending dose (MAD) portion of study, the safety of EYE103 will be assessed at escalating doses. Approximately 12 participants will be entered in this part of the study. In the second part of the study, called the dose finding pa... Read More
Gender:
All
Ages:
50 years and above
Trial Updated:
12/05/2023
Locations: Dallas, TX, Dallas, Texas
Conditions: Neovascular Age-related Macular Degeneration (NVAMD), Diabetic Macular Edema (DME)
Register for Updates
Cool Prime Comparative Effectiveness Study for Mild HIE
NCT04621279
Recruiting
To determine effectiveness of therapy to improve neurodevelopmental outcomes in infants with mild HIE. To determine the adverse effects of Therapeutic Hypothermia (TH) in mild HIE on the neonate and his/her family. Determine heterogeneity of the treatment effect across key subgroups obtained in the first 6 hours after birth prior to the decision to initiate therapy.
Gender:
All
Ages:
35 weeks and above
Trial Updated:
12/05/2023
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Mild Hypoxic Ischemic Encephalopathy of Newborn
Register for Updates
Study of ON 123300 in Patients With Advanced Cancer
NCT04739293
Recruiting
This study will investigate the safety of the drug ON 123300 at increasing doses to determine the best dose to use in future clinical trials.
Gender:
All
Ages:
18 years and above
Trial Updated:
12/05/2023
Locations: Mary Crowley Cancer Research, Dallas, Texas
Conditions: Solid Tumors, Adult
Register for Updates
Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies
NCT05705505
Recruiting
This study will assess the safety and efficacy of increasing doses of narazaciclib (ON 123300) in combination with the standard daily dose (2.5mg) of letrozole in patients with Recurrent Metastatic Low-grade Endometrioid Endometrial Cancer and other Gynecologic Malignancies.
Gender:
Female
Ages:
18 years and above
Trial Updated:
12/05/2023
Locations: Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas
Conditions: Endometrioid Endometrial Cancer
Register for Updates
Gemcitabine Versus Water Irrigation in Upper Tract Urothelial Carcinoma
NCT04865939
Recruiting
There is a high rate of intravesical (bladder) recurrence following extirpative surgery for upper tract urothelial carcinoma. There is no single established standard of care for prevention of intravesical recurrence; however, one protocol in common use involves the use of intravesical gemcitabine instilled into the bladder during surgery and prior to entry into the bladder. There are barriers to the use of gemcitabine, especially at lower volume centers. Some evidence suggests that intravesical... Read More
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
12/05/2023
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Urothelial Cancer of Renal Pelvis, Urothelial Carcinoma Ureter
Register for Updates
Emergency Department-Initiated Buprenorphine Validation Network Trial
NCT04225598
Recruiting
This study will (1) recruit, train and provide resources to approximately 30 Emergency Department (ED) sites throughout the U.S. using implementation facilitation strategies to provide ED-initiated buprenorphine (BUP) for patients presenting with opioid use disorder (OUD) who are not receiving medications for opioid use disorder (MOUD). Once implementation is adequately achieved, the sites will (2) conduct a randomized controlled trial (RCT) to compare the effectiveness of sublingual buprenorphi... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
12/01/2023
Locations: Parkland Memorial Hospital, Dallas, Texas
Conditions: Opioid-use Disorder
Register for Updates
TH1902 in Patients With Advanced Solid Tumors
NCT04706962
Recruiting
Open label first-in-human study of TH1902 in solid cancer, with 4 sequential parts: Part 1 (dose escalation): patients with recurrent advanced solid tumors (all comers) that have relapsed or are refractory to standard chemotherapy, surgery, radiation therapy, and for which no known effective therapies exist. Part 2 (expansion): selected patient populations with recurrent advanced TNBC, HR+ breast cancer, epithelial ovarian cancer, endometrial cancer, cutaneous melanoma, thyroid cancer, SCLC, p... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: Mary Crowley Cancer Research, Dallas, Texas
Conditions: Solid Tumor, TNBC - Triple-Negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Epithelial Ovarian Cancer, Endometrial Cancer, Cutaneous Melanoma, Thyroid Cancer, Small-cell Lung Cancer, Prostate Cancer, SORT1+ Cancers
Register for Updates
A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
NCT04951219
Recruiting
A 52-Week, Multi-center, Open-label, Active Treatment Extension Study to Evaluate Safety and Tolerability of Once Daily, Oral Administration of Resmetirom (MGL-3196)
Gender:
All
Ages:
18 years and above
Trial Updated:
11/28/2023
Locations: The Liver Institute At Methodist Dallas, Dallas, Texas +2 locations
Conditions: Non-Alcoholic Fatty Liver Disease
Register for Updates